Baseline characteristics for patients by treatment allocation
| . | Maintenance . | Observation . | Total . |
|---|---|---|---|
| Total, n (%) | 166 (100) | 166 (100) | 332 (100) |
| Median age, y | 57.8 | 57.7 | 57.8 |
| < 60, n (%) | 102 (61) | 103 (62) | 205 (62) |
| ≥ 60, n (%) | 64 (39) | 63 (38) | 127 (38) |
| Sex, n (%) | |||
| Female | 58 (35) | 56 (34) | 114 (34) |
| Male | 108 (65) | 110 (66) | 218 (66) |
| Stage at diagnosis, n (%) | |||
| I | 22 (13) | 22 (13) | 44 (13) |
| II | 61 (37) | 55 (33) | 116 (35) |
| III | 83 (50) | 89 (54) | 172 (52) |
| M component, n (%) | |||
| Other/missing | 6 (4) | 3 (2) | 9 (3) |
| IgA | 38 (23) | 33 (20) | 71 (21) |
| IgG | 98 (59) | 110 (66) | 208 (63) |
| Light chain only | 24 (14) | 20 (12) | 44 (13) |
| ECOG performance status, n (%) | |||
| 0 | 65 (39) | 55 (33) | 120 (36) |
| 1 | 92 (55) | 105 (63) | 197 (59) |
| 2 | 9 (5) | 6 (4) | 15 (5) |
| Myeloablative therapy, n (%) | |||
| Melphalan < 200 mg/m2 | 8 (5) | 2 (1) | 10 (3) |
| Melphalan 200 mg/m2 | 139 (83) | 142 (86) | 280 (84) |
| Missing | 20 (12) | 22 (13) | 44 (13) |
| Response to treatment, n (%) | |||
| Complete response | 24 (14) | 18 (11) | 42 (13) |
| Partial response | 142 (86) | 148 (89) | 290 (87) |
| Albumin, n (%) | |||
| Unknown/missing, < 35 g/L | 15 (9) | 9 (5) | 24 (7) |
| ≥ 35 g/L | 151 (91) | 157 (95) | 308 (93) |
| Bone lesions, n (%) | |||
| Unknown/missing or ≥ 1 lytic lesions | 117 (70) | 124 (75) | 241 (73) |
| Normal bone structure, solitary plasmacytoma, generalized osteoporosis | 49 (30) | 42 (25) | 91 (27) |
| . | Maintenance . | Observation . | Total . |
|---|---|---|---|
| Total, n (%) | 166 (100) | 166 (100) | 332 (100) |
| Median age, y | 57.8 | 57.7 | 57.8 |
| < 60, n (%) | 102 (61) | 103 (62) | 205 (62) |
| ≥ 60, n (%) | 64 (39) | 63 (38) | 127 (38) |
| Sex, n (%) | |||
| Female | 58 (35) | 56 (34) | 114 (34) |
| Male | 108 (65) | 110 (66) | 218 (66) |
| Stage at diagnosis, n (%) | |||
| I | 22 (13) | 22 (13) | 44 (13) |
| II | 61 (37) | 55 (33) | 116 (35) |
| III | 83 (50) | 89 (54) | 172 (52) |
| M component, n (%) | |||
| Other/missing | 6 (4) | 3 (2) | 9 (3) |
| IgA | 38 (23) | 33 (20) | 71 (21) |
| IgG | 98 (59) | 110 (66) | 208 (63) |
| Light chain only | 24 (14) | 20 (12) | 44 (13) |
| ECOG performance status, n (%) | |||
| 0 | 65 (39) | 55 (33) | 120 (36) |
| 1 | 92 (55) | 105 (63) | 197 (59) |
| 2 | 9 (5) | 6 (4) | 15 (5) |
| Myeloablative therapy, n (%) | |||
| Melphalan < 200 mg/m2 | 8 (5) | 2 (1) | 10 (3) |
| Melphalan 200 mg/m2 | 139 (83) | 142 (86) | 280 (84) |
| Missing | 20 (12) | 22 (13) | 44 (13) |
| Response to treatment, n (%) | |||
| Complete response | 24 (14) | 18 (11) | 42 (13) |
| Partial response | 142 (86) | 148 (89) | 290 (87) |
| Albumin, n (%) | |||
| Unknown/missing, < 35 g/L | 15 (9) | 9 (5) | 24 (7) |
| ≥ 35 g/L | 151 (91) | 157 (95) | 308 (93) |
| Bone lesions, n (%) | |||
| Unknown/missing or ≥ 1 lytic lesions | 117 (70) | 124 (75) | 241 (73) |
| Normal bone structure, solitary plasmacytoma, generalized osteoporosis | 49 (30) | 42 (25) | 91 (27) |